A comparison of the data in column 6 in the large table against row 4 in the smaller table displays that #ava6000 is clearly demonstrating therapeutic levels of Dox in the biopsy samples
#avct#avacta#ava6000
The ratios in column 7 display how much higher (as much as 125:1!) the concentration of Dox in the tumour compared with the bloodstream after administering #ava6000#avct#avacta#ava6000
@avacta’s AVA6000 vs straight Doxorubicin displays a MARKED reduction in frequency and severity of treatment emergent adverse events including severe adverse events such as anaemia, neutropenia, thrombocytopenia
#avct#avacta#ava6000
#ava3996#ava6000#AACR poster explainer video:
https://t.co/IuhrHUZuX7
AS: “We are focused on accelerating AVA3996 through to IND filing as soon as possible so that it can follow AVA6000 into the clinic next year."
#avct#avacta@avacta
2. Nice to see the straight comparison of 3996 against Bortezomib (AKA Velacade). 3996 demonstrating “HIGH efficacy” in FAP but, unlike Bortezomib, with “NO toxicity”.
#ava3996#avct#avacta#takeda#velacade#bortezomib
AFX001/AFX002 “Data will be presented at International Society for Cell & Gene Therapy, May 2023 (AffyXell and Avacta)” #avct#avacta#affyxell@avacta
For anyone questioning the authenticity of the “revolutionising” billboard, go to Drug Discovery Worlds YouTube page. It is the thumbnail image assigned to the ‘DDW at the Avacta open day 2022’ video: https://t.co/dkG1JlYcYH #avct#avacta